Abstract: A method for preparing 1,3-propanediol with a high space-time yield, in which A methyl 3-hydroxypropionate solution is pumped into a tubular fixed-bed reactor loaded with a surface modifier-coated nano-Cu-based catalyst for continuous hydrogenation to obtain a reaction mixture, where the catalyst includes Cu as active component, a metal oxide XOn/2 as additive and a SiO2—SnO2 composite carrier. The reaction mixture is subjected to rectification to separate light components from heavy components, where the light components include methanol, n-propanol, methyl propionate, methyl 3-hydroxypropionate and 1,3-propanediol, and the heavy components include 1,3-propanediol mono-propionate and 1,3-propanediol mono-3-hydroxypropionate. The heavy components are fed back to the tubular fixed-bed reactor for secondary hydrogenation, and the light components are separated to obtain 1,3-propanediol.

Abstract: The present disclosure relates to an application of Antarctic red pigment in a preparation of drugs for treatment and prevention of hyperuricemia, which belongs to the field of biomedicine. The present disclosure studies a fermentation product of existing fungi Geomycos sp. wnf-18C or Geomycos sp. wnf-15A, and finds that the Antarctic red pigment produced by the fermentation product has good therapeutic effects on hyperuricemia induced by high purines. Thus, this pigment has application value in the preparation of drugs for hyperuricemia induced by high purine.

Abstract: An information processing method is provided. The method is applied to a touch terminal capable of presenting a graphical user interface. The graphical user interface includes a virtual character and at least part of a game scene. The method includes: determining first orientation information of at least one target virtual object that satisfies a prompt trigger event in the game scene; determining a sub-identifier corresponding to the first orientation information in a first graphical identifier, wherein the first graphical identifier is set around the virtual character; and displaying the prompt trigger event graphically on the graphical user interface through the sub-identifier. A processing apparatus, an electronic device and a storage medium are also disclosed.

Abstract: The invention provides engineered mitochondria and a preparation method thereof, and relates to the technical field of mitochondria. The engineered mitochondria are formed by attaching exogenous cell membranes to outer membranes of exogenous mitochondria. The preparation method comprises the following steps: S1: extracting exogenous cell membranes from cells; S2: separating and extracting exogenous mitochondria from cells or tissue; and S3: mixing the separated and extracted exogenous mitochondria with the exogenous cell membranes in a specific ratio, thereby attaching the exogenous cell membranes to the outer membranes of the exogenous mitochondria to obtain the engineered mitochondria. The invention enables the production of engineered mitochondria with enhanced biological activity, exhibiting improved therapeutic effects on mitochondrial dysfunction-related disorders.

Abstract: The present invention pertains to pharmaceutical chemical field, and relates to a sterol derivative as well as preparation method and uses thereof. Specifically, the present invention relates to a compound of Formula I, or a pharmaceutically acceptable salt, ester or ether thereof, wherein, R1 is selected from the group consisting of —OH, ?O(carbonyl), H, and C1-C3 alkyl; R2 is selected from the group consisting of —OH, H, and C1-C3 alkyl; R3 is selected from the group consisting of —OH, ?O, H, and C1-C3 alkyl; R4 is selected from the group consisting of —OH, H, and C1-C3 alkyl; and none, one, two, three or four of R1, R2, R3, and R4 are —OH. The compound of the present invention can inhibit HMG-CoA reductase, tumor cells and lipase effectively, and is a potential drug for reducing blood-fat, antitumors, or for losing weight.

Abstract: The present invention pertains to pharmaceutical chemical field, and relates to a sterol derivative as well as preparation method and uses thereof. Specifically, the present invention relates to a compound of Formula I, or a pharmaceutically acceptable salt, ester or ether thereof, wherein, R1 is selected from the group consisting of —OH, ?O(carbonyl), H, and C1-C3 alkyl; R2 is selected from the group consisting of —OH, H, and C1-C3 alkyl; R3 is selected from the group consisting of —OH, ?O, H, and C1-C3 alkyl; R4 is selected from the group consisting of —OH, H, and C1-C3 alkyl; and none, one, two, three or four of R1, R2, R3, and R4 are —OH. The compound of the present invention can inhibit HMG-CoA reductase, tumor cells and lipase effectively, and is a potential drug for reducing blood-fat, antitumors, or for losing weight.

Abstract: A fully-automatic protein purification system device includes a chromatography unit, a first drive unit, a connecting pipeline, a locating unit, a second drive unit, a first container, a second container, a first valve, a second valve, and a control unit. The fully-automatic protein purification system device can fully automate the protein chromatography purification with a simple device structure and a low cost, has low requirements for the quality of a sample solution, will not cause blockage of a pipeline, has a wide application range, can greatly improve the automation of protein chromatography purification in the biology field, and can reduce the manual investment.

Abstract: The present invention pertains to pharmaceutical chemical field, and relates to a sterol derivative as well as preparation method and uses thereof. Specifically, the present invention relates to a compound of Formula I, or a pharmaceutically acceptable salt, ester or ether thereof, wherein, R1 is selected from the group consisting of —OH, ?O(carbonyl), H, and C1-C3 alkyl; R2 is selected from the group consisting of —OH, H, and C1-C3 alkyl; R3 is selected from the group consisting of —OH, ?O, H, and C1-C3 alkyl; R4 is selected from the group consisting of —OH, H, and C1-C3 alkyl; and none, one, two, three or four of R1, R2, R3, and R4 are —OH. The compound of the present invention can inhibit HMG-CoA reductase, tumor cells and lipase effectively, and is a potential drug for reducing blood-fat, antitumors, or for losing weight.

Abstract: A microfluidics-based nanoparticle synthesis system, a device and a synthesis method thereof are provided. The nanoparticle synthesis system comprises: a microfluidic chip; a reagent bottle which is connected with the microfluidic chip; and a flow control assembly comprising a pressure controller which is used for controlling the pressure in the reagent bottle. The system achieves high-accuracy flow control, and a microfluidic chip that can achieve high-efficiency and rapid mixing is also used in combination to finally achieve high-throughput and high-uniformity nanoparticle synthesis. A user may adjust the same instrument as required to achieve different throughputs without redesigning the instrument.

Abstract: The present invention pertains to pharmaceutical chemical field, and relates to a sterol derivative as well as preparation method and uses thereof. Specifically, the present invention relates to a compound of Formula I, or a pharmaceutically acceptable salt, ester or ether thereof, wherein, R1 is selected from the group consisting of —OH, ?O(carbonyl), H, and C1-C3 alkyl; R2 is selected from the group consisting of —OH, H, and C1-C3 alkyl; R3 is selected from the group consisting of —OH, ?O, H, and C1-C3 alkyl; R4 is selected from the group consisting of —OH, H, and C1-C3 alkyl; and none, one, two, three or four of R1, R2, R3, and R4 are —OH. The compound of the present invention can inhibit HMG-CoA reductase, tumor cells and lipase effectively, and is a potential drug for reducing blood-fat, antitumors, or for losing weight.

Abstract: The present invention pertains to pharmaceutical chemical field, and relates to a sterol derivative as well as preparation method and uses thereof. Specifically, the present invention relates to a compound of Formula I, or a pharmaceutically acceptable salt, ester or ether thereof, wherein, R1 is selected from the group consisting of —OH, ?O(carbonyl), H, and C1-C3 alkyl; R2 is selected from the group consisting of —OH, H, and C1-C3 alkyl; R3 is selected from the group consisting of —OH, ?O, H, and C1-C3 alkyl; R4 is selected from the group consisting of —OH, H, and C1-C3 alkyl; and none, one, two, three or four of R1, R2, R3, and R4 are —OH. The compound of the present invention can inhibit HMG-CoA reductase, tumor cells and lipase effectively, and is a potential drug for reducing blood-fat, antitumors, or for losing weight.

Abstract: The present invention pertains to pharmaceutical chemical field, and relates to a sterol derivative as well as preparation method and uses thereof. Specifically, the present invention relates to a compound of Formula I, or a pharmaceutically acceptable salt, ester or ether thereof, wherein, R1 is selected from the group consisting of —OH, ?O(carbonyl), H, and C1-C3 alkyl; R2 is selected from the group consisting of —OH, H, and C1-C3 alkyl; R3 is selected from the group consisting of —OH, ?O, H, and C1-C3 alkyl; R4 is selected from the group consisting of —OH, H, and C1-C3 alkyl; and none, one, two, three or four of R1, R2, R3, and R4 are —OH. The compound of the present invention can inhibit HMG-CoA reductase, tumor cells and lipase effectively, and is a potential drug for reducing blood-fat, antitumors, or for losing weight.

Abstract: A method for controlling game character is applied to a touch control terminal capable of rendering a graphical user interface, the graphical user interface includes a virtual character and at least part of a game scene. The method includes: at least one target virtual object that satisfies a prompt trigger event is determined (S1410); a sub-identifier corresponding to each of the at least one target virtual object in a first graphical identifier is determined, wherein the sub-identifier is used for graphically displaying the prompt trigger event on the graphical user interface (S1430); in response to a visual field adjustment touch instruction, a first presentation visual field of the game screen is changed to a second presentation visual field of the game screen determined according to direction information corresponding to the sub-identifier (S1450). An apparatus for controlling game character, an electronic device and a computer storage medium are also disclosed.

Abstract: A collapsible stent for an implantable prosthetic valve incorporates leaflet-supporting members having relatively large surface area in comparison to other members defining the remainder of the stent. The leaflet-supporting members may have openings extending through them. The valve leaflets may be attached to the stent so that an attached edge of each leaflet extends along the leaflet-supporting members and is attached to the members by polymer integral with the leaflet overlying the leaflet supporting members and extending into the openings of the leaflet supporting members. The secure attachment resists stress on the leaflets.

Abstract: Methods and compositions are described for producing a glucanase in transgenic plants and then incorporating parts of the transgenic plants in animal feed. The feed glucanase enzyme displays activity across a broad pH range, and tolerance to temperatures that are often encountered during the process of preparing animal feeds. Producing the enzyme in the transgenic plant enhances the thermal stability of the enzyme.

Abstract: A method for controlling game character is applied to a touch control terminal capable of rendering a graphical user interface, the graphical user interface includes a virtual character and at least part of a game scene. The method includes: at least one target virtual object that satisfies a prompt trigger event is determined (S1410); a sub-identifier corresponding to each of the at least one target virtual object in a first graphical identifier is determined, wherein the sub-identifier is used for graphically displaying the prompt trigger event on the graphical user interface (S1430); in response to a visual field adjustment touch instruction, a first presentation visual field of the game screen is changed to a second presentation visual field of the game screen determined according to direction information corresponding to the sub-identifier (S1450). An apparatus for controlling game character, an electronic device and a computer storage medium are also disclosed.

Abstract: An information processing method is provided. The method is applied to a touch terminal capable of presenting a graphical user interface. The graphical user interface includes a virtual character and at least part of a game scene. The method includes: determining first orientation information of at least one target virtual object that satisfies a prompt trigger event in the game scene; determining a sub-identifier corresponding to the first orientation information in a first graphical identifier, wherein the first graphical identifier is set around the virtual character; and displaying the prompt trigger event graphically on the graphical user interface through the sub-identifier. A processing apparatus, an electronic device and a storage medium are also disclosed.

Abstract: The present invention discloses preparation and use of a nanoparticle-doped RNA hydrogel targeting to a triple negative breast cancer (TNBC). The RNA hydrogel is a pure RNA system formed in a rolling circle transcription manner. The transcription process generates a large number of GC bonds, which provides a large number of sites for the introduction of DOX. The large number of RNA copy structures generated by rolling circle replication is a polyanionic aggregate. Due to the strong electronegativity of the polyanionic aggregate, electropositive MnO2@Ce6 nanoparticles are introduced, such that the colloid cationic MnO2@Ce6 particles can be stabilized by the polyanionic hydrogel, and thus target into a breast cancer cell for synergistic treatment. It can be used for a drug slow release system, has good biocompatibility, and has broad prospects in the fields of growth inhibition effects on targeted MDA-MB-231 tumor cells, inhibition of cancer metastasis and recurrence, and the like.